South and Central America Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro, and In-Vivo), Indication (Cancer, Autoimmune Diseases, Infecti

South and Central America Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro, and In-Vivo), Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Microbial Diseases, and Others), Application (Therapeutic Applications, Diagnostic Applications, and Research Applications), End-User (Hospitals, Research Institutes, and Others)

The South & Central America monoclonal antibodies market is expected to reach US$ 10,847.3 million by 2028 from US$ 5,584.2 million in 2021. The market is estimated to grow at a CAGR of 9.9% from 2021-2028.

According to the International AIDS Vaccine Initiative (IAVI) report, the development of m ABs is one of the fastest-growing segments of biomedical research. For records, more than 50 m ABs were licensed in the last six years, and in 2019, seven of the ten best-selling novel drugs for cancer and autoimmune diseases were m ABs. Further, with the growing number of non-communicable and infectious diseases, for which m ABs are or might prove effective treatment, there is certainly an accelerating demand for such products. For example, m ABs sales are predominant in South & Central America. As the percentage of m ABs in the development pipeline increases, more and more m ABs will enter the market, and the disparity in access between high-income countries and the rest of the world will worsen. Furthermore, a few combinations of m ABs are also being developed to address many diseases, including chronic infections and cancer. On the other hand, several counties are taking strong initiatives to shorten the regulatory process for m ABs effective for treating chronic diseases. For records, in early 2019, the CFDA approved three m ABs from domestic developers and ten m ABs from multinational pharmaceutical companies. Such factors are stimulating the uptake of m ABs, aiding the market significantly.

According to the NCBI report, monoclonal antibodies (m ABs) have been considered as an innovative technology for the treatment of some types of cancer, as they possess the capability of targeting and selectively killing tumor cells. For example, there was a retrospective analysis conducted based on consultation of the Brazilian Health Regulatory Agency (Anvisa) where these m ABs were characterized according to the target antigen, type of antibody, year of registration, therapeutic indications, and applicant. For records, in August 2021, Anvisa announced granting of emergency use authorization (EUA) for Celltrion’s “Regdanvimab (CT-P59)” for treating adults with mild-to-moderate COVID-19 and who do not require supplemental oxygen and are at higher risk of progression to severe COVID. As Brazil had the highest number of confirmed cases from COVID-19 in South and Central America with an average 35,000 cases per day and since the beginning of pandemic, at least 1 in 10 residents have been infected a total of 20,249,176 reported severe cases. Therefore, Celltrion’s monoclonal antibody-based product significantly reduces the risk of COVID-19 related hospitalization and deaths by 72% for patients at higher risk of progression to severe COVID-19 and 70% of all patients. Therefore, amid COVID-19 pandemic, monoclonal antibodies witnessed highest ever adoption in South and Central America regional market.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the monoclonal antibodies market. The South & Central America monoclonal antibodies market is expected to grow at a good CAGR during the forecast period.

South & Central America Monoclonal Antibodies Market Revenue and Forecast to 2028 (US$ Million)

South & Central America Monoclonal Antibodies Market Segmentation

By Source

Human Humanized Chimeric Murine By Production Method

In-Vitro In-Vivo By Indication

Cancer Autoimmune Diseases Infectious Diseases Inflammatory Diseases Microbial Diseases Others By Application

Therapeutic Applications Diagnostic Applications Research Applications By End-User

Hospitals Research Institutes Others By Country

South & Central America Brazil Argentina Rest of South & Central America Companies Mentioned

Novartis AG Pfizer Inc. Glaxo Smith Kline plc. Amgen Inc DAIICHI SANKYO COMPANY, LIMITED F. Hoffmann-La Roche Ltd. Astra Zeneca Bayer AG Bristol-Myers Squibb Company

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America monoclonal antibodies market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the South & Central America monoclonal antibodies market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.